News & Breakthroughs at Siteman
Stay informed with the latest cancer news and breakthroughs from Siteman Cancer Center. Our news feed provides timely updates on research breakthroughs, clinical trials, and community events.
Clinical News & Stories
Clinical, In the Media, Research
1,000th patient treated at Siteman with AI-enabled radiation therapy system
Combining artificial intelligence (AI) with advanced imaging, the technology supports more precise, personalized daily treatments by WashU Medicine physicians Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine has treated its 1,000th patient using state-of-the art radiation therapy technology that allows physicians to update a patient’s treatment plan on each day of treatment. Called adaptive […]
Clinical, In the Media, Research
Siteman recruiting participants for multi-cancer detection tests
National study aims to detect disease before symptoms appear Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine is recruiting participants for a national study of a new type of blood test aimed at detecting several types of cancer before symptoms appear. The tests could identify the presence of ovarian, pancreatic, bladder and other cancers […]
Clinical, Research
Vaccine Shows Promise Against Aggressive Breast Cancer
Clinical trial targeted recurrence of hard-to-treat triple-negative breast cancer A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington University School of Medicine in St. Louis with a therapy designed by Washington University researchers, the trial is the […]
Clinical, In the Media
New Outpatient Cellular Therapy Center Opens at Siteman Cancer Center
A new Outpatient Cellular Therapy Center has opened at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. With nine infusion beds and three infusion chairs, the center is on the eighth floor of Schoenberg Pavilion on the Washington University Medical Campus in the Central West End. The […]
Clinical, Patient Resource
Colon cancer surgery: what to expect and how to prepare
When it comes to colon cancer, surgery is the most common treatment. Types of colon cancer surgery depend on the stage of the cancer and where the cancer is in the colon. For early-stage colon cancers and young-onset colorectal cancer, surgeons may recommend minimally invasive surgery. For more advanced colon cancers, surgery may be performed […]
Clinical
Subtle signs of ovarian cancer women should look out for
The first symptoms of ovarian cancer are easy to miss, which is why it has long been called the “silent killer.” But ovarian cancer isn’t really a silent killer; the early signs are often ignored or mistaken for other benign conditions. Gynecologic symptoms for cervical, uterine and ovarian cancers are all easy to brush off, […]
Clinical
How Siteman approaches triple-negative breast cancer treatment
According to the American Cancer Society (ACS), triple-negative breast cancer (TNBC) accounts for 10-15 percent of all breast cancers. It develops more quickly, is more likely to spread and is harder to treat than other breast cancers. Because it’s such an aggressive cancer, TNBC has a poorer prognosis than other invasive breast cancers. What is […]
Clinical
How Siteman approaches metastatic breast cancer treatment
Finding out you have metastatic breast cancer (also known as advanced or stage IV breast cancer) can be very scary. While there is no cure, treatment can slow the cancer, extend the patient’s life and improve quality of life. What is metastatic breast cancer? Metastatic breast cancer refers to cancer that originated in the breast […]
Clinical
Siteman’s innovations in brain tumor surgery are advancing treatment
Clinical
Newly approved drug effective against lung cancer caused by genetic mutation
The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with […]